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Abstract
Castleman’s disease (CD) is a rare, localized or generalized, lymphoproliferative disorder with a frequent mediastinal
location, but possible in any lymph node or extra nodal site. It usually appears in young adults whilst it rarely
occurs in childhood. There are only about 100 pediatric cases published, five of them in Italy. We report 3 cases of
localized Castleman’s disease, investigated in our Department in a 3 years period and reviewed the literature.
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Background
Castleman’s disease (CD) is a rare and not well recognized
disease characterized by a massive growth of lymphoid tis-
sue of unknown etiology that was first described in 1954,
and subsequently better defined by Castleman in 1956
[1,2]. The disease usually presents in young adults and is
probably slightly more frequent in women. CD is classified
into two clinical subtypes: a localized and a multifocal sub-
type. CD may occur anywhere along the lymphatic system,
although the most common location (70%) is the mediasti-
num. Extrathoracic sites have been reported in the neck,
axilla, pelvis and retroperitoneum [3]. Surgery is the opti-
mal therapeutic approach only in the localized form, while
for unresectable or disseminated disease, partial surgical
resection, steroid, chemotherapy and radiotherapy have
been employed with some measurable success.
We report three cases of localized hyaline-vascular CD
in pediatric age observed in our Department in the last
3 years; a complete surgical resection was not feasible in
one of them and so various therapeutic attempts were
performed.
Case Reports
Case 1
GM, female, was admitted, at the age of 3.3 years, with an
asymptomatic left axillary mass showing a slow
progressive growth. At presentation she was in good gen-
eral conditions and the physical examination was normal.
Routine blood tests were all normal too. Radiological
examinations (chest X-ray, abdominal ultrasound, chest
CT scan) confirmed the adenopathy and excluded other
locations. After 2 months a complete surgical resection
was performed, and a single lymph node of 4 cm maxi-
mum diameter was removed. Histological assessments
indicated the diagnosis of hyaline-vascular CD (Figure 1A,
B). There has been no recurrence 48 months after
diagnosis.
Case 2
LG, male; at the age of 3.8 years an isolated palpable sub-
cutaneous tumefaction, sized 1 cm in maximum dia-
meter, appeared on his right blade shoulder. On
admission he was in good physical condition; routine
blood tests, abdominal ultrasound and chest X-ray were
all normal. After a follow-up period of 3 months, during
which the mass enlarged to a diameter of 2.5 cm, a com-
plete surgical resection was performed and two subcuta-
neous and intramuscular nodules, having maximum
diameter 2.5 and 1.2 cm respectively, were removed and
examined. Histology revealed a classic picture of hyaline-
v a s c u l a rC D( F i g u r e2 A , B ) .N or e c u r r e n c ew a sn o t e d
after a 36-month follow up.
Case 3
DA, male; at the age of 13 years a mass in the anterior
part of the neck was noted. He was admitted to an
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been suspected. A chest computed tomography (CT)
scan showed that the neck mass, with high contrast-
enhancement, originated in the anterior-superior med-
iastinum and caused a serious right dislocation of the
trachea (Figure 3A-D). A fine needle biopsy of this mass
was promptly performed, but it was not diagnostic, with
the detection of small normal lymphocytes only: conse-
quently the patient was referred to our Unit. The boy
was in good general condition, without any symptom as
fever, night sweats or weakness, and the physical exami-
nation, excluding the palpable mass of the anterior part
of the neck, was normal. All the blood tests, particularly
serum levels of LDH, ERS, CRP, ferritin, copper, immu-
noglobulins and IL-6 were within normal range: IL-6
was tested because of the atypical presentation of a
suspected lymphoma (no constitutional symptoms, no
superficial lymphadenopathy and a soft consistency of
the tumor). Abdominal ultrasound and
99 mTc-MDP
total body bone scan were both normal. After two
weeks, suspecting a mediastinal Hodgkin Lymphoma, an
open biopsy of the mass was performed; during the sur-
gical procedure massive bleeding occurred and the
hemoglobin level dropped from 12.3 to 8.7 gr/dl. No
other serious events occurred. The histology showed
the typical aspect of a hyaline-vascular CD (Figure 4A-
D). A second neck-chest CT scan and echocardiography
confirmed the tumor was not resectable, so, in consid-
eration of a formal request of treatment by the parents,
a prednisone treatment (25 mg × 3/day p.o. for two
months) was started: a chest CT evaluation revealed it
was completely ineffective. The same poor result was
Figure 1 Histology showed a follicular center exihibiting prominent hyalinized vessels, surrounded by concentric layers of
lymphocytes (A), dendritic follicular cells in the germinal center were positive for CD21 (B).
Figure 2 Histology showed small hyalinized germinal center within an expanded mantle zone (A), dendritic follicular cells in the
germinal center were CD21-positive (B).
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10 mg/week for 8 doses.
After prolonged and troublesome discussion with sur-
geons, an attempt of surgical excision was planned
through a left trap door incision. This approach con-
sisted of a left-anterior cervical access, median sternot-
omy and left-anterior thoracotomy that could provide
adequate exposure of the neurovascular structures [4].
The mass had a vascular aspect and encased the left
internal jugular vein and the carotid artery down into
the mediastinum. Repeated attempts to remove the
lesion caused massive and life-threatening bleeding;
therefore the procedure was prematurely interrupted
and an abundant transfusion of red blood cells was
performed.
Finally, after troubling discussion with the parents, the
boy underwent a 45 Gy course of 3D conformal radiation
therapy on the upper mediastinal mass, with standard frac-
tionation of 1.8 Gy per day. The treatment was delivered
through two antero-posterior, postero-anterior asymmetri-
cally weighted beam pairs of different energies in order to
encompass the mass into the 95% isodose. Particular care
was taken to avoid undue radiation delivery to the nearby
organs: right and left lungs received an average dose of 8
and 6.4 Gy respectively, while the spinal cord maintained
a maximum dose less than 45 Gy. A CT scan performed
at two months from the end of radiotherapy showed a
reduction of the mass by about 60% and a significant
improvement of tracheal dislocation: both were more evi-
dent in a second CT scan performed 3 months later. The
FDG-PET scan that initially revealed a mildly significant
uptake of the radiopharmaceutical of the residual disease
at three months from the end of radiotherapy, became
totally negative after a further 3 months, confirming the
effectiveness of our therapy choice. A further reduction of
the residual mass sizes and negative total body scan was
obtained six months later with neck-chest CT scan and
FDG-PET scan respectively. Now the boy is well, on a
Figure 3 CT scan showed that the neck mass, a multiple lymph node enlargement, with an high contrast-enhancement, originated in
the anterior-superior mediastinum and cause a serious right dislocation of the trachea (A-D).
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12 months after discontinuation of treatment.
Pathology Findings
Histologically all of our cases, diagnosed as hyaline-vas-
cular type of Castleman’s disease, showed a mass of lym-
phoid tissue with scattered abnormal lymphoid follicles,
which ranged in size from small to large. The germinal
centers were depleted and composed predominantly of
follicular dendritic cells and endothelial cells of hyali-
nized capillaries. Their appearance corresponds to that of
“hyaline vascular nodules”. Another peculiar finding was
the presence of more than one small germinal center
within a single follicle. There was a concentric layering of
lymphocytes at the periphery of the follicles with an
onion-skin appearance.
The interfollicular areas showed vascular proliferation
with numerous hyperplastic vessels of the postcapillary
venule type with hyaline material between vessels and
absence of sinuses. A small number of lymphocytes,
plasmacells, eosinophils and immunoblasts were present.
Immunohistochemically, positive CD21 and CD35
were seen in the large cells with vesicular nuclei (follicu-
lar dendritic cells) in the center of follicles, strong posi-
tive FVIII-related antigen was seen in the endothelium
of the interfollicular vessels, but only weak and focal
reaction was found in the hyaline vessels located in the
center of the follicles.
The immunoglobulin production by plasmacells was
polytypic and in the interfollicular areas large numbers
of suppressor T cells were found.
In summary the diagnostic features were small hyaline
germinal centers within an expanded mantle zone, as
well as a highly vascularized interfollicular network.
Discussion
CD is a disease of unknown etiology, first described by
C a s t l e m a ni n1 9 5 6[ 2 ]a n dc u r rently classified in two
Figure 4 Histology showed small germinal center depleted of follicular center B cells, and penetration by hyalinized venules (A);
follicular dendritic cell were evidenced by their strong immunoreactivity for CD 35 (B); immunoreactivity for CD20 (C) and CD3 (D)
was strongly positive.
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involved) and disseminated (two or more lymph nodal
groups involved). Localized disease seems to be much
more frequent, above all in the case of thoracic presenta-
tion [4,5]. There are three major histological subtypes:
hyaline-vascular CD (HV-CD), plasma cell CD (PC-CD)
and a plasmablastic variant associated with HHV8 and
HIV. The first is much more frequent (91-96%) [5,6].
The majority (57-91%) of localized disease is hyaline-vas-
cular [7,8]. Most cases of disseminated CD are PC-CD
variants or plasmablastic variants in HIV+ patients [8,9].
The prognosis of the disseminated PC-CD is worse
whereas disseminated variants with HV-CD histology or
with a mixed appearance between HV-CD and PC-CD
seem to have a better course [3,8-11].
Prevalence is estimated to be less than 1/100,000 [12].
There are some series where female sex is predominant
[4,13,14], but in many others there is no sex predilection
[6-8]. The peak of incidence is in the third and fourth
decade of life for localized CD and in the fourth and
fifth decade of life for disseminated CD [7,8,13].
It is postulated that the disease represents a reaction to
chronic viral antigenic stimulation with the bulk of evi-
dence pointing toward an interleukin-6 role, above all in
the form of the disease associated with systemic manifes-
tations [15-17]. The large majority of cases don’ts h o w
lymphocyte monoclonality [18]. In many cases the HHV-
8 has been postulated as the virus capable of causing the
disease, above all in multicentric cases [19,20].
Finally, there are many reports of association of the
multicentric type with HIV infection with a global inci-
dence of 4.3/10,000 patient-years [21,22].
The majority of HV-CD at presentation is asympto-
matic but, in some cases, fever, night sweat or weight loss
can be present; in contrast, if the localized disease has a
plasma cell histology, constitutional symptoms are very
frequent, as in the disseminated form [7,8]. The site of
presentation can be abdominal, mediastinal or peripheral
and the frequency of involvement reported in the litera-
ture is variable [6,8,23]. The CD located in the thorax
can be found in mediastinum (anterior above all, but
middle and posterior too) and, rarely, in the chest wall,
pleura, pericardium, intercostal space, and lung [5,24,25].
Usually the mediastinal masses are wide and most of the
thoracic cases are asymptomatic at presentation; some-
times there are symptoms connected to local pressure
from the mass (cough, chest pain, dyspnoea etc.). Inva-
sion and adherence to vessels and bronchi are common
patterns and often the mass proves difficult to complete
resection, as in our case [5]. When the location is abdom-
inal the presentation sometimes includes abdominal pain
[26].
T h ep l a s m ac e l l sa n d / o rt h em u l t i c e n t r i cC Dp r e s e n t
with a variety of constitutional symptoms: peripheral
lymphadenopathy, hepatosplenomegaly, weight loss, ane-
mia, asthenia, night sweats, fever, skin rash, lung disor-
der and kidney dysfunction [8,25,27].
Less common presentations are polyneuropathy, pleural
effusion, ascites etc. [23,28]. Typically there are also
laboratory abnormalities: elevated serum concentration of
gamma globulin and acute phase proteins, thrombocytosis,
elevated ESR, low serum albumin level, proteinuria, and,
sometimes, elevated IL-6, especially in the plasma cell
systemic disease [8].
Enhancement on CT images after intravenous admin-
istration is universally reported but it seems that the
enhancement is to a lesser degree in the plasma cell var-
i a n t .A tM R It h eT 1w e i g h t e di m a g e sa r ei s o i n t e n s eo r
slightly hyperintense relative to the skeletal muscle; the
hyperintensity is much more evident on T2 weighted
images [5].
About the therapy issue, it is difficult to draw defini-
tive conclusions for both local and disseminated CD,
but some broad indications can be found.
Since the recurrence of localized CD is very unusual
when the resection is complete, surgery is the preferred
treatment in these cases [6-8,29-31]. When a complete
resection is impossible, in the case of unicentric hyaline-
vascular disease, partial resection and/or, radiation therapy
with doses ranging from 27 to 45 Gy are a possibility
[7,32,33]. It has been reported that with these treatments
some patients can remain asymptomatic “long term” and
that, even in the case of mediastinal disease, simple partial
resection without any extra treatment has not been fol-
lowed by recurrence [7]. Surprisingly there are very few
cases where steroid therapy has been attempted, but this
could be explained by the fact that complete resection is
easily performed in all non-mediastinal sites and that
radiotherapy is traditionally preferred in the case of med-
iastinal lymphoma [33]. It is important to note, however,
that there are some case reports where the disease, with-
out any treatment, remains asymptomatic or shows a gra-
dual spontaneous improvement and even complete
remission [7,8]. The location of the lymphadenopathy has
no influence on the outcome [8].
Even though cases of spontaneous remission have been
described [11], the course of disseminated CD, especially
in the plasma cell form, is often reported poor due to
complications like infections, severe autoimmune anemia,
sarcoidosis, amyloidosis, POEMS syndrome (polyneuro-
pathy, organomegaly, endocrinopathy, monoclonal anti-
body, skin changes), and evolution into malignant
neoplasm, principally lymphoma, follicular dendritic cell
sarcoma or, especially in HIV positive patients, Kaposi
sarcoma [8,15,18,34,35].
In some more recent series, however, the prognosis
seems to have been better [7]. The treatment of the disse-
minated form is not well documented but chemotherapy
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against Hodgkin Lymphoma are the most commonly
used, even in childhood [36]. The role of radiotherapy is
more uncertain than in the localized form, since there
are cases where it proved to be useful and others where
there was no response [11,37]. In some cases steroids
alone can be sufficient for remission even though the
treatment must often be prolonged; it is possible that the
response to steroids can have a prognostic value
[8,10,38]. Finally there are some sporadic cases where
experimental therapies like autologous hematopoietic
stem-cell transplantation, rituximab, valganciclovir, toci-
lizumab (an anti-IL-6 receptor antibody), interferon-
alpha, anakinra - an IL-1RA agonist - and, more recently,
siltuximab, a new anti-IL-6 chimeric monoclonal anti-
body, have been used with some success [21,39-44].
Since the treatment of our first two patients was an easy
uncomplicated complete surgical resection, we should
add some comments about therapy strategies in our third
patient, that could not be surgically resected completely.
When this option is impossible the most important
aspects to consider are the volume and location of the
mass: probably in sites not “at risk” careful observation is
the best option and radiotherapy can be taken into
account in other cases.
Our experience also emphasizes the potential hazards of
surgical resection depending on the location and vascular
characteristics of the Castleman’s disease: the second sur-
gical attempt was prematurely stopped due to serious life-
threatening bleeding. Probably, a preoperative emboliza-
tion could be a safety precaution before of a surgical
approach on a HV-CD variant [31]. Between the two sur-
gical procedures we first attempted a trial with steroid
(prednisone 25 mg × 3/day) for 2 months, that totally
failed; subsequently we performed a trial with administra-
tion of vinblastine weekly for 8 doses, without any
response. After the ineffective surgical procedure we were
extremely troubled in the treatment decision making and,
finally, opted for local radiotherapy for the following con-
siderations: a) some authors reported the effectiveness of
lymphoma-like multiagent chemotherapy, such as CVAD
or CHOP schedule, but only in multicentric CD, that
represents a more aggressive clinical entity [7]; b) our
patient suffered from a localized CD, and radiotherapy, as
reported by some authors, can also achieve a good clinical
response [45]; c) our patient was a big pubertal male
(weight 68 Kg and height 171 cm), in which consequences
of breast exposure to radiation or growth abnormalities
are fairly improbable. On the contrary, the risk of cardiac
dysfunction, growth abnormalities and secondary malig-
nancies may limit the application of radiotherapy in other
pediatric patients (pre-pubertal and females).
Thus we planned local radiotherapy, choosing a total
dose of 45 Gy, that had good results, as previously
reported in the literature [45]. CT scan evaluation
showed a marked reduction of the mass and a signifi-
cant reduction of tracheal dislocation, and there was an
absolute disappearance of the radiopharmaceutical
uptake in the last FDG-PET scans, performed 6 and 12
months after the end of radiation treatment.
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